However, CRISPR-based therapies are now on the horizon for the treatment of debilitating diseases such as sickle cell disease [19], cancer [20], and, most recently, a rare condition called carbamoyl phosphate synthase 1 (CPS1) deficiency [21]. This evidence concerns the gene CPS1 and sickle cell disease.